Authors: Keiko Shinsako Tomoyuki Mizuno Tomohiro Terada Jun Watanabe Tomomi Kamba Eijiro Nakamura Osamu Ogawa Kenichi Inui
Publish Date: 2010/03/26
Volume: 15, Issue: 5, Pages: 512-514
Abstract
Sorafenib Nexavar® has been approved for the treatment of advanced renal cell carcinoma RCC and hepatocellular carcinoma There is little information on the dosage adjustment of sorafenib for patients with endstage renal failure Herein we have examined the effect of hemodialysis on the pharmacokinetics of sorafenib and its major active metabolite M2 and assessed sorafenibrelated toxicity throughout the therapy The patient was a 54yearold man who was diagnosed with advanced RCC Pharmacokinetic analysis was carried out on days 9 and 183 The patient had stable disease on day 77 and showed progression on day 181 He has received about 6 months of continuous treatment with sorafenib 800 mg/day without any clinically relevant toxicity The pharmacokinetic parameters of sorafenib such as C max and AUC0–12 on day 183 were in the range of the reference values reported in patients with normal renal function Our results suggest that sorafenib administered at a dose of 400 mg twice per day was well tolerated at least for 6 months for a patient undergoing hemodialysis
Keywords: